Commercial Information Circulars
24-hour hotline : 23 922 922
e-mail address : enquiry@tid.gov.hk
Ref. : EIC 631/2/5/1
26 April 2024
Dear Sirs,
Commercial Information Circular No. 324/2024
The Mainland of China : Notice Concerning Issues Related to Optimising the Application for Marketing and Registration of Overseas-produced Drugs Already Marketed Domestically to be Shifted to Domestic Production
The National Medical Products Administration issued on 19 April 2024 the "Notice Concerning Issues Related to Optimising the Application for Marketing and Registration of Overseas-produced Drugs Already Marketed Domestically to be Shifted to Domestic Production". Please refer to the Appendix (pdf format) for the notice (available in Chinese only).
ENQUIRIES
2.If you have any questions on the content of the document mentioned in this circular, please contact the issuing authority of the Mainland. For other questions on this circular, please contact Mainland Branch (I) (tel: 2398 5444) of the Department.
Yours faithfully,
(Miss Sindy LEE)
for Director-General of Trade and Industry
Note: While every effort is made to ensure the accuracy of the above information, the Department cannot guarantee this to be so and will not be held liable for any reliance placed on the same.